Scarica l'app Stockscreener
1.51
7.93%
-0.13
Dopo l'orario di chiusura:
1.52
0.01
+0.66%
60 Degrees Pharmaceuticals Inc Borsa (SXTP) Ultime notizie
60 Degrees Pharmaceuticals to study tafenoquine against Lyme disease By Investing.com - Investing.com India
60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria - The Manila Times
60 Degrees Pharmaceuticals to study tafenoquine against Lyme disease - Investing.com
Major Breakthrough: Anti-Malaria Drug Tafenoquine Being Tested for Lyme Disease Treatment - Stock Titan
60 Degrees Pharmaceuticals' Warrant Gambit: Balancing Liquidity and Longevity - AInvest
60 Degrees Pharmaceuticals closes $5 million public offering By Investing.com - Investing.com South Africa
60 Degrees Pharmaceuticals closes $5 million public offering - Investing.com Australia
60 Degrees Pharmaceuticals Secures $5 Million in Public Offering - AInvest
60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering - Stock Titan
Form 424B4 60 DEGREES PHARMACEUTICA - StreetInsider
Trade Desk Shares Surge 15% Amid S&P 500 Inclusion - AInvest
What makes 60 Degrees Pharmaceuticals Inc. Equity Warrant stock price move sharplyFree Stock Market Insider Analysis - Newser
Why 60 Degrees Pharmaceuticals Inc. Equity Warrant stock attracts strong analyst attentionProfitable Yet Secure Picks - Newser
60 Degrees Pharmaceuticals Prices $10 Million Public Offering - citybiz
How 60 Degrees Pharmaceuticals Inc. stock performs during market volatilityFree Stock Market Real-Time Monitoring - Newser
SXTP Crashes 21%—What’s Behind the Unraveling of 60 Degrees Pharma? - AInvest
SXTP Stock’s Upward Trend: What Lies Ahead? - StocksToTrade
60 Degrees Pharmaceuticals' $10M Raise: A High-Risk Gamble on Capital Efficiency? - AInvest
60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering - The Manila Times
What makes 60 Degrees Pharmaceuticals Inc. stock price move sharplyFree Step-by-Step Investment Guide - Newser
60 Degrees Pharmaceuticals Secures Up to $10M Funding: New Capital Injection for Infectious Disease Breakthroughs - Stock Titan
Why 60 Degrees Pharmaceuticals Inc. stock attracts strong analyst attentionFree Stock Investment Discussion Area - Newser
What makes Recursion Pharmaceuticals Inc. stock price move sharplyFree Smart Investment Opportunities - Newser
Why BridgeBio Pharma Inc. stock attracts strong analyst attentionFree Professional Portfolio Management - Newser
60 Degrees Pharma targets $245 million market for babesiosis treatment - Investing.com Australia
60 Degrees Pharma targets $245 million market for babesiosis treatment By Investing.com - Investing.com South Africa
Major FDA Development: Pierre Fabre Assumes Control of Atara's EBV Cell Therapy Program After BLA Resubmission - Stock Titan
Why Trade Desk Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - Benzinga
60 Degrees Pharmaceuticals Inc (SXTP) Stock Soars 77.83% on MUMS Designation Plans - AInvest
Breakthrough Babesiosis Drug ARAKODA Targets $1.1B Market Opportunity, FDA Filing Next Year - Stock Titan
How 60 Degrees Pharmaceuticals Inc. Equity Warrant stock performs during market volatilityWeekly Big Movers - Newser
60 Degrees Pharmaceuticals’ (SXTP) Sell (E+) Rating Reiterated at Weiss Ratings - Defense World
Sypris Solutions (NASDAQ:SYPR) vs. IES (NASDAQ:IESC) Head-To-Head Analysis - Defense World
Reviewing International Flavors & Fragrances (NYSE:IFF) and H. B. Fuller (NYSE:FUL) - Defense World
New Semiconductor SPAC Launches $100M IPO: Silver Pegasus Targets Tech Acquisitions - Stock Titan
60 Degrees Pharmaceuticals: Leveraging MUMS Designation to Tackle Canine Babesiosis and Drive Growth - AInvest
60 Degrees to Submit FDA MUMS Request for Tafenoquine in Canine Babesiosis - MarketScreener
60 Degrees Pharmaceuticals stock surges on canine babesiosis treatment plans - Investing.com
First FDA-Approved Oral Treatment for Dangerous Tick-Borne Dog Disease Could Be Coming in 2025 - Stock Titan
Biotech Giant Vertex Pharmaceuticals Schedules Q2 2025 Earnings CallKey Details for Investors - Stock Titan
Trinity Capital Sets Q2 2025 Earnings Call: Live Webcast and Phone Access Available - Stock Titan
Breakthrough Brain Cancer Drug REYOBIQ Achieves 80% Tumor Reduction in Phase 1 Trial, Advances to Next Stage - Stock Titan
Eupraxia's Revolutionary EoE Drug Enters Critical Phase 2b Trial: Direct Injection Method Shows Promise - Stock Titan
Eton's New Pediatric Drug Solution Advances Toward FDA Approval, Targeting $1B Market Opportunity - Stock Titan
GAMMA Investing LLC Grows Stock Position in M/I Homes, Inc. (NYSE:MHO) - Defense World
FDA Breakthrough: First-Ever Oral Drug for HAE Attacks Ends Decade of Injectable-Only Treatments - Stock Titan
Prudential Financial Sets Q2 Earnings Date: $1.5T Asset Manager Reports July 30 - Stock Titan
Prospect Capital Expands Consumer Credit Portfolio with Strategic $115M QC Holdings Buyout - Stock Titan
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Given “Sell (E+)” Rating at Weiss Ratings - Defense World
Xenon Makes Major League Move: Dual Russell Index Inclusion Opens Door to $10.6T Investment Pool - Stock Titan
Major Breakthrough: Corvus Expands Atopic Dermatitis Drug Development into Chinese Market with New Trial Approval - Stock Titan
First Patient Shows Zero Toxicity in CERo's Groundbreaking Cancer Immunotherapy Trial - Stock Titan
Quince Therapeutics Secures $22M Premium Financing as Phase 3 Trial Hits 95 Patient Milestone - Stock Titan
$452M Deal: Processa's Phase 2 Gastroparesis Drug Shows Promise, Attracts Major Licensing Interest - Stock Titan
Elite Pharmaceuticals Eyes $27B Market After Breakthrough Generic Drug Study Success - Stock Titan
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Cut to Sell at Wall Street Zen - Defense World
FDA Green Lights Amneal's $201M Generic Eye Drug: Q3 2025 Launch Set for Pred Forte Alternative - Stock Titan
Windtree's $1.5 Billion Oncology Drug Deal Signals Major Strategic ShiftSee Full Terms - Stock Titan
Karat Packaging Insiders Plan Massive 1.5M Share Sale: Management Team Cashing Out - Stock Titan
60 Degrees Pharmaceuticals and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Daily Jeffersonian
Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners’ Spring 2025 Spotlight Series - The Holland Sentinel
Eskay Mining 2025 Exploration Campaign Begins Later This Month - The Oklahoman
Research Analysts Set Expectations for SXTP Q2 Earnings - Defense World
0.64%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):